We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+31.47%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
-$294M
Cap. Flow
-$772M
Cap. Flow %
-28.57%
Top 10 Hldgs %
31.56%
Holding
109
New
24
Increased
20
Reduced
34
Closed
23

Top Buys

Rank Stock Value
1
ATEC icon
Alphatec Holdings
ATEC
+$39.7M
2
HUM icon
Humana
HUM
+$32.6M
3
MAZE
Maze Therapeutics
MAZE
+$29.9M
4
AVTX icon
Avalo Therapeutics
AVTX
+$25.8M
5
ALMR
Alamar Biosciences
ALMR
+$24.5M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$78.9M
2
NUVL
Nuvalent
NUVL
+$71.8M
3
CGON icon
CG Oncology
CGON
+$66.7M
4
ARGX icon
argenx
ARGX
+$55.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$46.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.44%
2 Miscellaneous 3.68%
3 Financials 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
51
Elevance Health
ELV
$85.5B
$20.9M 0.77%
53,960
-8,120
-13% -$3.01M
TECX
52
Tectonic Therapeutic
TECX
$696M
$20.5M 0.76%
596,900
-250,251
-30% -$7.35M
DYN icon
53
Dyne Therapeutics
DYN
$4.68B
$20.5M 0.76%
921,598
-760,400
-45% -$14.1M
IMCR icon
54
Immunocore
IMCR
$1.89B
$16.6M 0.61%
+521,327
New +$15.4M
ARGX icon
55
argenx
ARGX
$64B
$16.4M 0.61%
17,707
-67,232
-79% -$55.5M
CLDX icon
56
Celldex Therapeutics
CLDX
$3.07B
$16.2M 0.6%
436,646
-919,436
-68% -$29.7M
OVID icon
57
Ovid Therapeutics
OVID
$547M
$15.9M 0.59%
+5,919,464
New +$15.3M
MNKD icon
58
MannKind Corp
MNKD
$1.27B
$14.7M 0.55%
+3,458,429
New +$11.2M
QURE icon
59
uniQure
QURE
$3.38B
$13.9M 0.51%
+301,652
New +$7.9M
XFOR icon
60
X4 Pharmaceuticals
XFOR
$401M
$13.6M 0.5%
2,922,754
-350,200
-11% -$1.44M
ORIC icon
61
Oric Pharmaceuticals
ORIC
$1.37B
$13.2M 0.49%
1,214,540
+86,500
+8% +$784K
KNSA icon
62
Kiniksa Pharmaceuticals
KNSA
$6.09B
$11.8M 0.43%
183,822
-88,700
-33% -$4.6M
OCS icon
63
Oculis Holding
OCS
$678M
$11.6M 0.43%
+834,183
New +$18.9M
ACRS icon
64
Aclaris Therapeutics
ACRS
$885M
$11.3M 0.42%
2,142,348
+443,232
+26% +$1.98M
SPTX
65
Seaport Therapeutics
SPTX
$1.29B
$10.9M 0.4%
+500,000
New +$8.8M
VOR icon
66
Vor Biopharma
VOR
$1.34B
$10.6M 0.39%
573,104
+106,330
+23% +$1.61M
SRZN icon
67
Surrozen
SRZN
$264M
$10.1M 0.38%
390,753
-5,347
-1% -$147K
IMUX icon
68
Immunic
IMUX
$210M
$9.91M 0.37%
+645,010
New +$7.96M
HLXC
69
Helix Acquisition Corp III
HLXC
$238M
$9.54M 0.35%
900,000
– –
IONS icon
70
Ionis Pharmaceuticals
IONS
$10.1B
$9.26M 0.34%
116,762
-14,100
-11% -$1.06M
DGX icon
71
Quest Diagnostics
DGX
$26.8B
$9.16M 0.34%
+43,200
New +$8.48M
ANL
72
Adlai Nortye Group ADS
ANL
$890M
$9.14M 0.34%
+795,214
New +$9.68M
TENX icon
73
Tenax Therapeutics
TENX
$79.7M
$8.5M 0.31%
+584,412
New +$7.47M
KARD
74
Kardigan Inc
KARD
$1.87B
$7.16M 0.26%
+300,000
New +$6.94M
AMAN
75
Amanat Acquisition Corp
AMAN
$104M
$7.11M 0.26%
+700,000
New +$7.07M
1 2
3
4 5

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q2 2026 Portfolio in Review

As of Q2 2026, Braidwell held 109 positions worth $2.7B, down 9.8% from $3B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Braidwell withdrew a net $772M in Q2 2026, closing 23 positions and reducing 34 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $78.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Braidwell opened a new position in Humana worth $45.5M.

  • Braidwell's largest Q2 2026 buy was Humana: 114,500 shares worth $45.5M.
  • Braidwell added most to Alphatec Holdings in Q2 2026, an estimated $39.7M increase.
  • Braidwell's biggest Q2 2026 reduction was argenx, cutting an estimated $55.5M.
  • Braidwell fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $78.9M.
  • Braidwell's ten largest holdings make up 32% of its $2.7B portfolio in Q2 2026.
  • Braidwell opened 24 new positions and closed 23 in Q2 2026.
  • Braidwell's portfolio value fell 9.8% quarter-over-quarter to $2.7B.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.